DOCSLIB.ORG

US5708038.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

IIIUS005708038A United States Patent 19 11 Patent Number: 5,708,038 Davis 45 Date of Patent: Jan. 13, 1998 54 METHOD OF USING ALOEVERA ASA Hart et al. (1988) J. of Ethnopharmacology 23:61-71. BOLOGICAL VEHICLE Malini and Vanithakumari (1992) J. Ethnopharmacology 75) Inventor: Robert H. Davis, King of Prussia, Pa. 36:51. 73) Assignee: Univera Pharmaceuticals, Inc., Malini and Vanithakumari (1990) J. Ethnopharmacology Broomfield, Colo. 28:221. 21 Appl. No.: 662,654 Primary Examiner-Carlos Azpuru 22 Filed: Jun. 13, 1996 Attorney, Agent, or Firm-Swanson & Bratschun L.L.C. (51 int. C. m. A61K 47/42 57 ABSTRACT 52 U.S. Cl. .................. 514/783 58) Field of Search .......................... 514/783; 424/195.1 The present invention provides a method for using Aloevera as a biological vehicle for the delivery of drugs. In one 56 References Cited embodiment Aloe vera is used as a biological vehicle to U.S. PATENT DOCUMENTS deliver the estrogen, B-estradiol and the androgen, testoster one propionate. The present invention also provides a 5,565,199 10/1996 Page et al. ........................... 424/195.1 method of treating symptoms and diseases mediated by OTHER PUBLICATIONS hormonal deficiencies or amenable to treatment by hor Davis et al. (1991) JAPMA 81:1. mones using Aloe vera as a biological vehicle. Elghamry and Shihata (1966) Plant Medica 14:352. Fjösne et al. (1990) The Prostate 17:1. 34 Claims, 3 Drawing Sheets 200 160 120 80 Control 40 HESSESE 0.005 0.01 0.1 Estradiol Benzoate (ug) U.S. Patent Jan. 13, 1998 Sheet 1 of 3 5,708,038 8 O 4 O 0.005 0.01 0.1 Estradiol Benzoate (ug) Fig. 1 U.S. Patent Jan. 13, 1998 Sheet 2 of 3 5,708,038 Saix Cxtax: stratic: Bexoatx (i.ii gag: :8:aisie:xxxixe .ii isg, six w x8 (38 kg Estradio: Bersaxate: {{..ii agri-kick Wera. 388 Big M s X U.S. Patent Jan. 13, 1998 Sheet 3 of 3 5,708,038 200 180 160 140 120 0.1 0.25 0.5 1.0 Testosterone Propionate (mg) Fig. 3 5,708,038 1. 2 METHOD OF USING ALOE WERA ASA pharmacologic agents. Ideally a vehicle should be nonirri BOLOGICAL WEHICLE tating and compatible with common medications. Criteria for vehicle selection include solubility of the active agent in FIELD OF INVENTION the vehicle and the ability of the vehicle to penetrate 5 physical barriers such as the stratum corneum and the lipid The present invention relates generally to a method of portion of the cell membrane. Consideration must also be using Aloe vera as a biological vehicle for the delivery of given to any interactions between the vehicle and the active drugs. Specifically, this invention describes a method of agent, the efficiency with which the vehicle releases the using Aloe vera as a biological vehicle to deliver the incorporated active ingredient, the molecular size and the estrogenic hormone, 3-estradiol, and the androgenic composition of the vehicle. Traditional vehicles for subcu hormone, testosterone. Further included in this invention is 10 taneous administration include oils which tend to be irritat a method for treating hormonal deficiencies and conditions ing. Aloe vera has been shown to be nonirritating and amenable to treatment with hormones using Aloe Vera as a nontoxic when injected subcutaneously in mice, even at biological vehicle for delivery of the hormone. massive doses. Occasionally, a vehicle will have a synergistic effect, such BACKGROUND OF THE INVENTION 15 that the final sum total of the activity in each system is Aloe is an intricate plant which contains many biologi greater than the sum of the components. As stated above, this cally active substances. (Cohen et al. in Wound Healing/ is highly desirable in that less of the pharmacologic agent Biochemical and Clinical Aspects, 1st ed. WB Saunders, can be used to achieve the same effect, thereby reducing or Philadelphia (1992)). Over 300 species of Aloe are known, eliminating any side effects associated with higher dosages. most of which are indigenous to Africa. Studies have shown The estrogens are a group of hormones which promote that the biologically active substances are located in three proliferation and growth of specific cells in the body and are separate sections of the aloe leaf-a clear gel fillet located responsible for the development and maintenance of sec in the center of the leaf, in the leaf rind or cortex of the leaf ondary female sex characteristics. The estrogens are mainly and in a yellow fluid contained in the pericyclic cells of the 25 responsible for cellular proliferation and growth of the vascular bundles, located between the leaf rind and the tissues of the sexual organs and of other tissues related to internal gel fillet, referred to as the latex. Historically, Aloe reproduction. Estrogens also participate in the menstrual products have been used in dermatological applications for cycle. Naturally occurring estrogens, such as B-estradiol, the treatment of burns, sores and other wounds. These uses estrone and estriol, are steroids produced primarily by the have stimulated a great deal of research in identifying 30 ovaries. B-Estradiol (referred to herein as estradiol) is compounds from Aloe plants that have clinical activity, involved in the maturation and cyclic function of accessory especially anti-inflammatory activity. (See, e.g., Grindlay sex organs and the development of the duct system in and Reynolds (1986).J. of Ethnopharmacology 16:117-151; mammary glands. Of the estrogen hormones, estradiol has Hart et al. (1988).J. of Ethnopharmacology 23:61-71). As a the greatest physiological activity. When administered to result of these studies there have been numerous reports of 35 ovariectomized mice, estrogens induce estrous and increase Aloe compounds having diverse biological activities, uterine weight. Studies have shown that microgram amounts including anti-tumor activity, anti-gastric ulcer, anti of estradiol can increase the weight of the immature rat diabetic, anti-tyrosinase activity, (See, e.g. Yagi et al. (1977) uterus in as few as six hours. (Astwood (1938) Anat. Rec. Z. Naturforsch 32c:731-734), and antioxidant activity 70:25). (International Application Serial No. PCT/US95/07404). In hypogonadal women and menopausal women the level Recent research has also shown that Aloe vera, a term of estrogens in the blood decreases, causing a number of used to describe the extract obtained from processing the symptoms, including nervousness, depression, irritability entire leaf, isolated from the Aloe vera species of Aloe can and insomnia. There is also evidence that diminished estro be used as a vehicle for delivering the corticosteroid, gen levels contributes to a number of diseases, such as hydrocortisone, administered both topically and 45 atherosclerosis and osteoporosis. Presently, estrogen subcutaneously, to the site of inflammation. (Davis et al. replacement therapy is the only effective treatment for relief (1991) JAPMA 81:1). Davis et al. studied the topical and of the symptoms associated with decreased estrogen levels. systemic anti-inflammatory activity of Aloe vera alone and Estrogens also have a protective effect against ischemic in combination with hydrocortisone acetate. This study heart disease, (Martin et al. (1993) PS.E.B.M. 202:288), revealed that Aloevera contributed in an additive way to the tend to decrease the risk of coronary artery disease and have activity of the steroid, suggesting that Aloe vera may be a favorable effect on plasma lipid and high density lipopro useful as a biological vehicle for hydrocortisone. The sig teins (antiatherogenic effect) in menopausal women. nificance of this finding is that if used in combination with Currently, estrogen hormones are therapeutically used to Aloe vera, the dosage of the steroid can be reduced, while treat any disorder attributable to estrogen deficiencies or any maintaining its biological activity, thereby reducing or 55 disorders amenable to estrogen therapy, such as various eliminating any toxic side effects associated with higher functional ovarian disorders, osteoporosis, certain coronary dosages. These studies also revealed that Aloe vera assists in disorders in women, problems and discomforts associated the penetration of hydrocortisone through the stratum cor with menopause, and certain types of cancer. Estrogens are neum. Since Aloe vera contains many hydrophilic also used in oral contraceptives. compounds, such as enzymes, amino acids and Estrogens can be administered orally, by intramuscular or carbohydrates, as well as, hydrophobic compounds, such as subcutaneous injection or by subcutaneous implantation. vitamins and sterols, Davis et al. postulate that pharmaco Astwood has established an estradiol response curve for logic agents of both solubilities can be placed in Aloe vera mice of between 0.002 ug to 0.1 g per day. The dose and carried through the epidermal barrier. (Davis et al. response curve for humans, as well as other animals, can be (1991) JAPMA 81:1). 65 extrapolated from these results by taking into account the A vehicle is a substance, usually without biological greater body weight of the person or animal under consid activity, which is used as a medium for the administration of eration. 5,708,038 3 4 Problems associated with estrogen therapy include; pre The present invention also includes an improved method menstrual tension, weight gain, fat deposition, fallopian tube for the prevention and treatment of symptoms and diseases blockage, increased risk of endometrial cancer and increased mediated by estrogen and androgen deficiencies or amenable risk of gall bladder disease. The risk of endometrial cancer to treatment with estrogen or androgen in patients suffering is dependant upon both the amount and duration of therefrom. This method comprises administration of athera treatment, thus estrogens are typically administered at the peutically effective amount of estrogen or androgen, lowest dose that will control symptoms. respectively, in combination with Aloe vera.
Recommended publications
  • The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus Cyanogenys

    The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus Cyanogenys

    W&M ScholarWorks Dissertations, Theses, and Masters Projects Theses, Dissertations, & Master Projects 1970 The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus cyanogenys William F. McConnell College of William & Mary - Arts & Sciences Follow this and additional works at: https://scholarworks.wm.edu/etd Part of the Physiology Commons Recommended Citation McConnell, William F., "The Influence of Hypothalamic Steroid Implants on Ovulation and Ovarian Growth and Function in the Iguanid Lizard, Sceleporus cyanogenys" (1970). Dissertations, Theses, and Masters Projects. Paper 1539624685. https://dx.doi.org/doi:10.21220/s2-1smx-cy32 This Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Dissertations, Theses, and Masters Projects by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. THE INFLUENCE OF HYPOTHALAMIC STEROID IMPLANTS ON OVULATION AND OVARIAN GROWTH AND FUNCTION IN THE IGUANID LIZARD, SCELOPORUS CYANOGENYS A Thesis Presented to The Faculty of the Department of Biology The College of William and Mary in Virginia In Partial Fulfillment Of the Requirements for the Degree of Master of Arts By William F. McConnell 1970 ProQuest Number: 10625114 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0

    35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0

    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
  • Effects of Histone Deacetylase Inhibitors on Estradiol-Induced Proliferation and Hyperplasia Formation in the Mouse Uterus

    Effects of Histone Deacetylase Inhibitors on Estradiol-Induced Proliferation and Hyperplasia Formation in the Mouse Uterus

    539 Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus Andrei G Gunin, Irina N Kapitova and Nina V Suslonova Department of Obstetrics and Gynecology, Medical School Chuvash State University, PO Box 86, 428034, Cheboksary, Russia (Requests for offprints should be addressed to A G Gunin; Email: [email protected]) Abstract It is suggested that estrogen hormones recruit mechanisms of mitotic and bromodeoxyuridine-labelled cells in luminal controlling histone acetylation to bring about their effects and glandular epithelia, in stromal and myometrial cells. in the uterus. However, it is not known how the level of Levels of estrogen receptor- and progesterone receptors histone acetylation affects estrogen-dependent processes in in uterine epithelia, stromal and myometrial cells were the uterus, especially proliferation and morphogenetic decreased in mice treated with estradiol and trichostatin A changes. Therefore, this study examined the effects of or sodium butyrate. Expression of -catenin in luminal histone deacetylase blockers, trichostatin A and sodium and glandular epithelia was attenuated in mice treated butyrate, on proliferative and morphogenetic reactions in with estradiol with trichostatin A or sodium butyrate. Both the uterus under long-term estrogen treatment. Ovari- histone deacetylase inhibitors have similar unilateral effects; ectomized mice were treated with estradiol dipropionate however the action of trichostatin A was more expressed (4 µg per 100 g; s.c., once a week) or vehicle and tricho- than that of sodium butyrate. Thus, histone deacetylase statin A (0·008 mg per 100 g; s.c., once a day) or sodium inhibitors exert proliferative and morphogenetic effects of butyrate (1% in drinking water), or with no additional estradiol.
  • How to Study Male and Female Rodents

    How to Study Male and Female Rodents

    How to Study Female and Male Rodents Jill B. Becker, PhD Molecular and Behavioral Neuroscience Institute Department of Psychology University of Michigan Ann Arbor, Michigan © 2018 Becker How to Study Female and Male Rodents 7 Introduction Becker, 2016). When a sex difference is found, some NOTES This chapter discusses how to think about and investigators will want to determine more about the determine the appropriate manipulations and neurobiological processes that are responsible for the procedures for investigating sex differences in, and differences. the effects of gonadal hormones on, experimental outcomes in adult rats and mice. I will also discuss Effect of Gonadal Hormones on estrous cycles, surgical procedures, and hormone a Trait treatments. I will conclude with a discussion of One of the next questions that will arise is whether variability and statistical methods that can be used gonadal hormones have an effect on the trait. Two to minimize animal numbers when adding sex as a approaches can help determine whether this is biological variable to your research. the case. One can examine whether the female’s behavior varies with the estrous cycle. Alternatively, What Is a Sex Difference? one can remove the gonads by ovariectomy (OVX) The first question researchers usually ask is whether or castration (CAST) and then selectively replace there is a sex difference in a trait. The answer to this hormones. We will address the estrous cycle first. question is not a simple “yes” or “no”; it turns out to be more complicated. As illustrated in Figure 1A, Determining Estrous Cycle Stages males and females can exhibit different traits, as is The estrous cycle is the product of the hypothalamic- true for reproduction.
  • (12) United States Patent (10) Patent No.: US 6,503,894 B1 Dudley Et Al

    (12) United States Patent (10) Patent No.: US 6,503,894 B1 Dudley Et Al

    USOO6503894B1 (12) United States Patent (10) Patent No.: US 6,503,894 B1 Dudley et al. (45) Date of Patent: Jan. 7, 2003 (54) PHARMACEUTICAL COMPOSITION AND 5,460.820 A 10/1995 Ebert et al. METHOD FOR TREATING 5,610,150 A 3/1997 Labrie HYPOGONADISM 5,629,021. A 5/1997 Wright 5,641,504. A 6/1997 Lee et al. (75) Inventors: Robert E. Dudley, Kenilworth, IL 5,643,899 A 7/1997 Elias et al. (US); S. George Kottayil, Long Grove, (List continued on next page.) IL (US); Olivier Palatchi, L'Hayles FOREIGN PATENT DOCUMENTS Roses (FR) DE 3238984 10/1982 (73) Assignees: Unimed Pharmaceuticals, Inc., EP O581.587 A2 2/1994 Marietta, GA (US); Laboratories EP O197753 10/1996 Besins Iscovesco, Herndon, VA (US) EP O804926 4/1997 FR 2515041 4/1983 (*) Notice: Subject to any disclaimer, the term of this FR 2518879 7/1983 patent is extended or adjusted under 35 FR 2519252 7/1983 U.S.C. 154(b) by 0 days. FR 2.705572 12/1994 GB 2109231 6/1983 (21) Appl. No.: 09/651,777 WO WO 93/25168 A1 12/1993 WO 9408590 4/1994 (22) Filed: Aug. 30, 2000 WO 9421230 9/1994 WO 9421271 9/1994 (51) Int. Cl................................................. A61K 31/56 WO WO-96/27372 A1 * 9/1996 .......... A61 K/31/21 (52) U.S. Cl. ........................................ 514/178; 514/177 WO 9636339 11/1996 (58) Field of Search ................................. 514/178, 396, WO 9743989 11/1997 514/406, 415, 177 WO 98O8547 3/1998 WO 9824451 6/1998 (56) References Cited WO WO 98/34621 A1 8/1998 U.S.
  • Γ Agonists on Estradiol-Induced Proliferation and Hyperplasia Fo

    Γ Agonists on Estradiol-Induced Proliferation and Hyperplasia Fo

    229 Effects of peroxisome proliferator activated receptors- and - agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus A G Gunin, A D Bitter, A B Demakov, E N Vasilieva and N V Suslonova Department of Obstetrics and Gynecology, Medical School, Chuvash State University, P.O. Box 86, Cheboksary 428034, Russia (Requests for offprints should be addressed to A G Gunin; Email: [email protected]) Abstract It is suggested that the action of peroxisome proliferator- animals treated with estradiol and rosiglitazone for 30 days, activated receptors (PPARs) cross-talks with estrogen uterine mass was increased, abnormal uterine glands and signaling in the uterus. However, it is not known how atypical endometrial hyperplasia were found more often PPAR agonists affect estrogen-dependent processes in and levels of estrogen receptors- and -catenin were the uterus, especially proliferation and morphogenetic decreased. In animals treated with estradiol and fenofibrate changes. The effects of agonists of PPAR- and - on for 30 days, uterine mass was decreased, most of the proliferative and morphogenetic reactions in the uterus uterine glands had a normal structure, no cases of atypical under short- and long-term estrogen treatments were hyperplasia were diagnosed, proliferative activity was therefore examined. Ovariectomized mice were treated declined and the levels of estrogen receptors- and with estradiol dipropionate (4 µg/100 g, s.c., once a week) -catenin were markedly higher. Treatment with rosi- or vehicle and rosiglitazone (PPAR- agonist) or fenofi- glitazone or fenofibrate did not affect the serum estradiol brate (PPAR- agonist) or with no additional treatment level in the mice which received estradiol together with for 2 days or for 30 days.
  • New Long-Acting Androgens

    New Long-Acting Androgens

    World J Urol (2003) 21: 306–310 DOI 10.1007/s00345-003-0364-x TOPIC PAPER Louis J. Gooren New long-acting androgens Received: 16 September 2003 / Accepted: 17 September 2003 / Published online: 9 October 2003 Ó Springer-Verlag 2003 Abstract Testosterone substitution treatment aims to are usually irreversible. The consequence is that life-long replace physiological actions of endogenous testosterone androgen replacement is required. Patient compliance by steadily maintaining physiological blood levels of with life-long androgen replacement depends on conve- testosterone. The underlying conditions rendering nient pharmaceutical formulations ensuring continuity androgen replacement necessary are usually irreversible. of androgen replacement. The benefits of androgen The consequence is that almost life-long androgen replacement therapy are clear, but the delivery of tes- replacement is required. Patient compliance with life- tosterone to hypogonadal men in a way that approxi- long androgen replacement depends on convenient mates normal levels and patterns still poses a therapeutic pharmaceutical formulations ensuring continuity of challenge. Among experts, there is consensus that the androgen replacement. Therefore, they must be conve- major goal of testosterone substitution is ‘‘to replace nient in usage with a relative independence of medical testosterone levels at as close to physiological concen- services. In elderly man, safety of androgen replacement trations as is possible’’ [18]. General agreements about therapy is a concern but in younger subjects (below the such an androgen replacement therapy are (1) a delivery age of 50 years) side effects of androgens are usually of the physiological amount of testosterone (3-10 mg/d); minimal. For them, long-acting testosterone prepara- (2) consistent levels of testosterone, 5a-dihydrotestos- tions are well suited.
  • Use of Estrogen-Dihydropyridine Compounds For

    Use of Estrogen-Dihydropyridine Compounds For

    Europaisches Patentamt J European Patent Office © Publication number: 0 220 844 Office europeen des brevets A2 EUROPEAN PATENT APPLICATION © Application number: 86307536.2 © int. ci.<: A61K 31/57 A61 K , 31/565 , A61K 31/44 © Date of filing: 01.10.86 The title of the invention has been amended © Applicant: UNIVERSITY OF FLORIDA (Guidelines for Examination in the EPO, A-lll, 207 Tigert Hall 7.3). Gainesville Florida 32611 (US) @ Inventor: Bodor, Nicholas S. ® Priority: 22.10.85 US 790159 7211 Southwest 97th Lane Gainesville Florida 32608(US) © Date of publication of application: Inventor: Estes, Kerry S. 06.05.87 Bulletin 87/19 5604 Southwest 83rd Drive Gainesville Florida 32608(US) © Designated Contracting States: Inventor: Simpkins, James W. AT BE CH DE ES FR GB GR IT LI LU NL SE 1722 Northwest 11th Road Gainesville Florida 32605(US) © Representative: Pendlebury, Anthony et al Page, White & Fairer 5 Plough Place New Fetter Lane London EC4A 1HY(GB) © Use of estrogen-dihydropyridlne compounds for weight control. © The invention provides the use of a compound of the formula [E-DHC] (I) or a non-toxic pharmaceutically acceptable salt thereof, wherein [E] is an estrogen and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating, lipoidal form of a dihydropyridines*pyridinium salt redox carrier in the preparation of a medicament for controlling mammalian body weight. Novel compositions for weight control comprising a compound of formula (I) or its salt are also disclosed. A preferred compound for use herein is an I estradiol derivative, namely, 1 7/3-[(1 -methyl-1 ,4-dihydro-3-pyridinyl)carbonyloxy]estra-1 ,3,5(1 0)-trien-3-ol.
  • Network-Based Characterization of Drug-Protein Interaction Signatures

    Network-Based Characterization of Drug-Protein Interaction Signatures

    Tabei et al. BMC Systems Biology 2019, 13(Suppl 2):39 https://doi.org/10.1186/s12918-019-0691-1 RESEARCH Open Access Network-based characterization of drug-protein interaction signatures with a space-efficient approach Yasuo Tabei1*, Masaaki Kotera2, Ryusuke Sawada3 and Yoshihiro Yamanishi3,4 From The 17th Asia Pacific Bioinformatics Conference (APBC 2019) Wuhan, China. 14–16 January 2019 Abstract Background: Characterization of drug-protein interaction networks with biological features has recently become challenging in recent pharmaceutical science toward a better understanding of polypharmacology. Results: We present a novel method for systematic analyses of the underlying features characteristic of drug-protein interaction networks, which we call “drug-protein interaction signatures” from the integration of large-scale heterogeneous data of drugs and proteins. We develop a new efficient algorithm for extracting informative drug- protein interaction signatures from the integration of large-scale heterogeneous data of drugs and proteins, which is made possible by space-efficient representations for fingerprints of drug-protein pairs and sparsity-induced classifiers. Conclusions: Our method infers a set of drug-protein interaction signatures consisting of the associations between drug chemical substructures, adverse drug reactions, protein domains, biological pathways, and pathway modules. We argue the these signatures are biologically meaningful and useful for predicting unknown drug-protein interactions and are expected to contribute to rational drug design. Keywords: Drug-protein interaction prediction, Drug discovery, Large-scale prediction Background similar drugs are expected to interact with similar pro- Target proteins of drug molecules are classified into a pri- teins, with which the similarity of drugs and proteins are mary target and off-targets.
  • Steroidal Estrogens

    Steroidal Estrogens

    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
  • Pharmaceuticals and Medical Devices Safety Information No

    Pharmaceuticals and Medical Devices Safety Information No

    Pharmaceuticals and Medical Devices Safety Information No. 300 March 2013 Executive Summary Published by Translated by Pharmaceutical and Food Safety Bureau, Pharmaceuticals and Medical Devices Agency Ministry of Health, Labour and Welfare Office of Safety I For full text version of Pharmaceuticals and Medical Devices Safety Information (PMDSI) No. 300, interested readers are advised to consult the PMDA website for upcoming information. The contents of this month's PMDSI are outlined below. 1. Implementation of the “Risk Management Plan” Preparation of the Risk Management Plan (RMP) will be introduced for new drugs and biosimilars/follow-on biologics for which approval applications are submitted on or after April 1, 2013. This section of the full text introduces the outline of the system and future actions and encourages healthcare professionals to utilize the Risk Management Plan. 2. Revision of Precautions (No. 244) Revisions of Precautions etc. for the following pharmaceuticals: Estradiol (ESTRANA, Julina, DIVIGEL, FEMIEST), Estradiol Benzoate, Estradiol Valerate, Estradiol Dipropionate, Estriol (oral dosage form), Estriol Tripropionate, Conjugated Estrogens, Estradiol/Norethisterone Acetate, Estradiol/Levonorgestrel, Testosterone/Estradiol, Testosterone Enanthate/Estradiol Valerate, Testosterone Enanthate/Testosterone Propionate/Estradiol Valerate, Ethinylestradiol, Norethisterone/Mestranol (preparation with the indication for climacteric disturbance), Propafenone Hydrochloride, Purified Human Menopausal Gonadotrophin, Human Menopausal Gonadotrophin, Human Chorionic Gonadotrophin, Follitropin Beta (Genetical Recombination), Follitropin Alfa (Genetical Recombination), Estriol (injectable dosage form, preparations for vaginal application), Clomifene Citrate, Gonadorelin Acetate (1.2 mg, 2.4 mg), Cyclofenil 3. List of Products Subject to Early Post- marketing Phase Vigilance (as of March 2013) A list of products subject to Early Post-marketing Phase Vigilance as of March 1, 2013 will be provided in section 3 of the full text.